These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6832840)

  • 1. In vitro activity of new cephalosporins against multi-resistant gram-negative bacteria.
    Fainstein V; Le Blanc B; Bodey GP
    Infection; 1983; 11 Suppl 1():S20-2. PubMed ID: 6832840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers.
    Jones RN; Pfaller MA; Allen SD; Gerlach EH; Fuchs PC; Aldridge KE
    Diagn Microbiol Infect Dis; 1991; 14(4):361-4. PubMed ID: 1889187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative activity of seven extended-spectrum cephalosporins against gram-negative bacilli from blood cultures.
    Norris SM; Guenthner SH; Wenzel RP
    J Antimicrob Chemother; 1985 Aug; 16(2):183-8. PubMed ID: 3934124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of gentamicin sensitive and resistant gram negative bacilli to ceftazidime.
    Bremner DA
    Pathology; 1987 Jul; 19(3):274-6. PubMed ID: 3124067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of ceftazidime and ceftriaxone.
    Keenholtz SL; Jacobus NV; Tally FP; Gorbach SL
    Clin Ther; 1983; 5(6):603-16. PubMed ID: 6313195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activities of third-generation cephalosporins.
    Fass RJ
    Arch Intern Med; 1983 Sep; 143(9):1743-5. PubMed ID: 6615095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro comparison of ceftazidime and nine other antimicrobial agents against hospital strains of Gram-negative bacteria.
    Wilkinson LD; Gentry LO
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():53-6. PubMed ID: 19802969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative activity of ceftizoxime against aminoglycoside-resistant aerobic gram-negative bacilli.
    Gómez-Lus R; Rubio MC; García C; Gómez-Lus ML; Alejandre MC
    Drugs Exp Clin Res; 1987; 13(3):155-9. PubMed ID: 3497792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria.
    Thornsberry C
    Am J Med; 1985 Aug; 79(2A):14-20. PubMed ID: 3927723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
    Giamarellou H
    Am J Med; 1986 Jun; 80(6B):126-37. PubMed ID: 3088998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
    Chen MJ; Wang H;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cefotiam and cefazolin activity against Gram-negative bacilli.
    Ogawa M; Hama M; Kosaki G; Shimatani M; Suginaka H
    J Antimicrob Chemother; 1979 Nov; 5(6):681-5. PubMed ID: 395155
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in vitro activity and beta-lactamase stability of cefpirome (HR 810), a pyridine cephalosporin agent active against staphylococci, Enterobacteriaceae and Pseudomonas aeruginosa.
    Neu HC; Chin NX; Labthavikul P
    Infection; 1985; 13(3):146-55. PubMed ID: 3928497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
    van Klingeren B
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the antibacterial activity of nine cephalosporins against Enterobacteriaceae and nonfermentative gram-negative bacilli.
    Verbist L
    Antimicrob Agents Chemother; 1976 Oct; 10(4):657-63. PubMed ID: 984801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro studies with ceftazidime against aerobic gram-negative bacilli and Bacteroides fragilis group.
    Acuna G; Johnston J; Young LS; Martin WJ
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():83-9. PubMed ID: 19810170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic gram-negative bacilli.
    Chong Y; Lee K; Kwon OH
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():21-9. PubMed ID: 8150765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro antimicrobial activity of Cefpirome: a new fourth-generation cephalosporin against clinically significant bacteria.
    Hafeez S; Izhar M; Ahmed A; Zafar A; Naeem M
    J Pak Med Assoc; 2000 Aug; 50(8):250-2. PubMed ID: 10992706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.